{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:50:34Z","timestamp":1779313834514,"version":"3.51.4"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T00:00:00Z","timestamp":1259280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective either as monotherapy or in combination with drugs from the other major classes. In this review we analyze and review the information already gained with Aliskiren, raises questions regarding the advantages of DRIs as monotherapy compared to marketed ACEIs and ARBs, their potential added value in combination with other RAAS modulators and other still unproven benefits in relation to prorenin and renin receptor biology.<\/jats:p>","DOI":"10.3390\/ph2030118","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T06:03:28Z","timestamp":1259388208000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?"],"prefix":"10.3390","volume":"2","author":[{"given":"Salvatore","family":"Novo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Cardiovascular Diseases, University Hospital \u201cPaolo Giaccone\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Fazio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiovascular Diseases, University Hospital \u201cPaolo Giaccone\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Raccuglia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiovascular Diseases, University Hospital \u201cPaolo Giaccone\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjhyper.2007.04.001","article-title":"Aliskiren. New prospective","volume":"20","author":"Sealey","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s12325-009-0050-5","article-title":"Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension","volume":"26","author":"Riccioni","year":"2009","journal-title":"Adv. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200847080-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of aliskiren","volume":"47","author":"Vaidyanathan","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Persson, F., Rossing, P., Reinhard, H., Juhl, T., Stehouwer, C.D., Schalkwijk, C., Danser, A.J., Boomsma, F., Frandsen, E., and Parving, H.H. (2009). Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care, Epub ahead of print.","DOI":"10.2337\/dc09-0168"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"D\u00fcsing, R., and Sellers, F. (2009). ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr.Med. Res. Opin., Epub ahead of print.","DOI":"10.1185\/03007990903152045"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0025-7125(03)00129-9","article-title":"What have we learned from the current trials?","volume":"88","author":"Abbott","year":"2004","journal-title":"Med. Clin. North. Am."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Andersen, K., Weinberger, M.H., Constance, C.C., Ali, M.A., Jin, J.F., Prescott, M.F., and Keefe, D.L. (2009). Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J. Renin. Angiotensin Aldosterone Syst., Epub ahead of print.","DOI":"10.1177\/1470320309342407"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Peixoto, A.J., and Orias, M. (2009). Is there a role for direct renin inhibitors in chronic kidney disease?. Curr. Opin. Nephrol. Hypertens., Epub ahead of print.","DOI":"10.1097\/MNH.0b013e32832e3183"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Abassi, Z., Winaver, J., and Feuerstein, G.Z. (2009). The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality. Biochem.Pharmacol., Epub ahead of print.","DOI":"10.1016\/j.bcp.2009.05.018"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Palatini, P., Jung, W., Shlyakhto, E., Botha, J., Bush, C., and Keefe, D.L. (2009). Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study. J. Hum. Hypertens., Epub ahead of print.","DOI":"10.1038\/jhh.2009.38"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MAJ.0b013e31819b3a80","article-title":"New therapeutic options in patients prone to hypertension: a focus on direct Renin inhibition and aldosterone blockade","volume":"337","author":"Basile","year":"2009","journal-title":"Am. J. Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320309102747","article-title":"Review: renal protection by inhibition of the renin-angiotensin-aldosterone system","volume":"10","author":"Berl","year":"2009","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1185\/03007990802259354","article-title":"A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects","volume":"24","author":"Vaidyanathan","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11906-008-0037-7","article-title":"Now that we have a direct renin inhibitor, what should we do with it?","volume":"10","author":"Stanton","year":"2008","journal-title":"Curr Hypertens. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MNH.0b013e32830baa9b","article-title":"Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?","volume":"17","author":"Gaddam","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Stanton, A.V., Dicker, P., and O'Brien, E.T. (2009). Aliskiren Monotherapy Results in the Greatest and the Least Blood Pressure Lowering in Patients With High- and Low-Baseline PRA Levels, Respectively. Am. J. Hypertens., Epub ahead of print.","DOI":"10.1038\/ajh.2009.114"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1751-7176.2009.00114.x","article-title":"Combination therapy with various combinations of aliskiren, Valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone","volume":"11","author":"Geiger","year":"2009","journal-title":"J. Clin. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/HJH.0b013e32832be593","article-title":"Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial","volume":"27","author":"Schmieder","year":"2009","journal-title":"J. Hypertens."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ki.2009.105","article-title":"Aliskiren: A novel renoprotective agent or simply an alternative to ACE inhibitors?","volume":"76","author":"Wiggins","year":"2009","journal-title":"Kidney Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08038020802507290","article-title":"Efficacy of aliskiren\/hydrochlorothiazide single-pill combination in aliskiren non-responders","volume":"2","author":"Nickenig","year":"2008","journal-title":"Blood Press Suppl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/jhh.2008.162","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review","volume":"23","author":"Musini","year":"2009","journal-title":"J. Hum. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol.Dial. Transplant"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1470320309342733","article-title":"Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension","volume":"10","author":"Doulton","year":"2009","journal-title":"J. Renin. Angiotensin. Aldosterone Syst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00003495-200969070-00004","article-title":"Aliskiren\/hydrochlorothiazide combination: in mild to moderate hypertension","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs"},{"key":"ref_28","first-page":"453","article-title":"Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors","volume":"5","author":"Pimenta","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CIA.S3216","article-title":"Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension","volume":"4","author":"Andersen","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1432-2277.2009.00897.x","article-title":"Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation","volume":"22","author":"Freiberger","year":"2009","journal-title":"Transpl. Int."}],"updated-by":[{"DOI":"10.3390\/ph4101293","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T00:00:00Z","timestamp":1259280000000}}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/2\/3\/118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T06:56:19Z","timestamp":1754290579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/2\/3\/118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,12]]}},"alternative-id":["ph2030118"],"URL":"https:\/\/doi.org\/10.3390\/ph2030118","relation":{"correction":[{"id-type":"doi","id":"10.3390\/ph4101293","asserted-by":"object"}]},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}